



(51) International Patent Classification:

C07H 19/00 (2006.01) C07H 19/167 (2006.01)
C07H 19/052 (2006.01) C07H 21/00 (2006.01)

(21) International Application Number:

PCT/US2013/038703

(22) International Filing Date:

29 April 2013 (29.04.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/649,766 21 May 2012 (21.05.2012) US

(71) Applicant: **AGILENT TECHNOLOGIES, INC.**
[US/US]; Intellectual Property Administration, P. O. Box
7599, Loveland, CO 80537-0599 (US).

(72) Inventors; and

(71) Applicants (for US only): **HILL, Kenneth, W.** [US/US];
PO Box 7599, Loveland, CO 80537-0599 (US). **MOK-
LER, Victor, R.** [US/US]; PO Box 7599, Loveland, CO
80537-0599 (US).

(74) Agent: **ZHANG, Yin, Philip**; Milstein Zhang & Wu LLC,
2000 Commonwealth Ave., Suite 400, Newton, MA 02466
(US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES




FIG. 2

(57) Abstract: An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligonucleotide derivative are disclosed. wherein R³ is a first oligonucleotide; R¹ is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide; R² is a linker or a direct bond; Z¹ is NR⁴, S, or O, and Z² is NR⁴ or S, wherein R⁴ is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl. A method includes: synthesizing an oligonucleotide derivative comprising an amino or thiol group; and reacting a 3,4-dialkoxycyclobutene-1,2-dione with the oligonucleotide derivative to produce an oligonucleotide-squarate mono-conjugate.

COMPOSITIONS AND METHODS FOR CONJUGATING OLIGONUCLEOTIDES

Priority Claims and Related Patent Applications

[0001] This application claims the benefit of priority from U.S. Provisional Application Serial No. 61/649,766, filed on May 21, 2012, the entire content of which is incorporated herein by reference in its entirety.

Field of the Invention

[0002] The present application relates generally to the field of reagents, synthesis and purification of oligonucleotides. More particularly, the invention relates to compositions of oligonucleotide derivatives and methods for conjugating oligonucleotides.

Background of the Invention

[0003] Many methods are available for conjugating oligonucleotides with other molecules. These methods typically involve attachment of a reactive moiety on the target entity to be coupled with the oligonucleotide. The target entities with the reactive moieties are often made separately, usually by organic synthesis methods, and purified before use.


[0004] In each case the oligonucleotides are modified with appropriate functional groups for reacting with the reactive moieties on the target entities. Modifications of oligonucleotides are often accomplished by making special phosphoramidites and/or modified bases, and incorporating them into the oligonucleotide sequences at the desired points. Many of these amidite reagents contain functional groups that require protecting groups for the coupling of these reagents to the oligonucleotides. These protecting groups must be removed before the subsequent conjugation reaction occurs. Alternatively, the reactive moieties on the target entities may be created before the conjugation to the oligonucleotides.

[0005] Most of current coupling chemistries involve the use or creation of hydrolytically and/or oxidatively unstable species of at least one of the conjugation partners. This is a problem under conditions (typically in aqueous solutions) needed for conjugation with the oligonucleotides (or protein, or any organic insoluble/ water soluble species).

Newer conjugation chemistries may generate a novel structure upon reaction. For example, U.S. Patent No. 6,737,236, issued to Pieken et al., discloses cycloaddition reactions for the conjugations of biomolecules. One example, a 1,3-dipolar cycloaddition conjugation between an alkyne and an azide (later labeled under the general term “Click” chemistry by Sharpless et. al. *Angew. Chem. Int. Ed.* 40: 2004 (2001) produces a substituted triazine as part of the conjugation product. These new chemical entities can be a problem if the oligonucleotide conjugates are used in humans because these new chemical entities may cause toxicity unrelated to the oligonucleotide products.

Summary of the Invention

[0006] One aspect of the invention relates to oligonucleotide derivatives having the structure of formula (A):



wherein R^3 is a first oligonucleotide; R^1 is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide; R^2 is a linker or a direct bond; Z^1 is NR^4 , S, or O, and Z^2 is NR^4 or S, wherein R^4 is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl.

[0007] In some embodiments of the invention, R^2 is a (C_1 - C_{12}) linker attached to a 5' hydroxy group, a 3' hydroxy group, or an exocyclic amino group on a nucleobase of the first oligonucleotide. In some embodiments of the invention, Z^2 is NH. In some embodiments of the invention, R^1 is a (C_1 - C_{12}) alkyl and Z^1 is O.

[0008] In some embodiments of the invention, R^1 is a 1K – 40K polyethylene glycol and Z^1 is NH. In some embodiments of the invention, R^1 is a second oligonucleotide and Z^1 is NH, wherein the second oligonucleotide may be complementary to the first oligonucleotide.

[0009] Another aspect of the invention relates to methods for conjugating oligonucleotides. A method in accordance with one embodiment of the invention includes: synthesizing an oligonucleotide derivative comprising an amino or thiol group; and reacting a

3,4-dialkoxycyclobutene-1,2-dione with the oligonucleotide derivative to produce an oligonucleotide-squarate mono-conjugate.

[0010] In some embodiments of the invention, a method further comprises reacting the oligonucleotide-squarate mono-conjugate with a target entity selected from a polyethylene glycol, a peptide, a protein, a polysaccharide, or a second oligonucleotide.

[0011] In some embodiments of the invention, the oligonucleotide comprises a second amino or thiol group at a second location in the oligonucleotide derivative, the method further comprising forming an intra-oligonucleotide crosslink creating a cyclic structure.

[0012] Other aspects and advantages of the invention will be apparent from the following description and the appended claims.

Brief Description of Drawings

[0013] **FIG. 1** shows squaric acid and various reactions with the squaric acid.

[0014] **FIG. 2** shows a reaction between a modified oligonucleotide and a squaric acid diester in accordance with one embodiment of the invention.

[0015] **FIG. 3** shows conjugation of an oligonucleotide-squarate mono-adduct with a target entity (e.g., R-NH₂) in accordance with one embodiment of the invention.

[0016] **FIG. 4** shows conjugation of an oligonucleotide-squarate mono-adduct with various target entities in accordance with embodiments of the invention.

[0017] **FIG. 5** shows conjugation of two complimentary RNA stands, one with a 5' amine, the other with a 3' amine using the described squarate coupling procedure

[0018] **FIG. 6** shows conjugation of an oligonucleotide-squarate mono-adduct with various secondary amine target entities in accordance with embodiments of the invention.

Definitions

[0019] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms and symbols of nucleic acid chemistry, biochemistry, genetics, and molecular biology used herein follow those of standard treatises and texts in the field, e.g. Kornberg and Baker, DNA Replication, Second Edition (W.H. Freeman, New York, 1992); Lehninger, Biochemistry, Second Edition (Worth Publishers, New York, 1975); Strachan and

Read, Human Molecular Genetics, Second Edition (Wiley-Liss, New York, 1999); Eckstein, editor, Oligonucleotides and Analogs: A Practical Approach (Oxford University Press, New York, 1991); Gait, editor, Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, 1984); Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory, 1989); and the like. Still, certain terms are defined below for the sake of clarity and ease of reference.

[0020] The term “nucleoside”, as used herein, refers a modified or naturally occurring deoxyribonucleoside or ribonucleoside or any chemical modifications thereof. Modifications of the nucleosides include, but are not limited to, 2'-, 3'- and 5'-position sugar modifications, 5- and 6-position pyrimidine modifications, 2-, 6- and 8-position purine modifications, modifications at exocyclic amines, substitution of 5-bromo-uracil, and the like. Nucleosides can be suitably protected and derivatized to enable oligonucleotide synthesis by methods known in the field, such as solid phase automated synthesis using nucleoside phosphoramidite monomers, H-phosphonate coupling or phosphate triester coupling.

[0021] The term “nucleotide”, as used herein, refers to a modified or naturally occurring deoxyribonucleotide or ribonucleotide. Nucleotide is a nucleoside as defined above having one or several phosphates or substituted phosphates attached at the 5'-, 2'- or 3'-positions. Nucleotides typically include purines and pyrimidines, which include thymidine, cytidine, guanosine, adenine and uridine.

[0022] The term “oligonucleotide”, as used herein, refers to a polynucleotide formed from a plurality of linked nucleotide units as defined above. The nucleotide units each include a nucleoside unit linked together via a phosphate linking group. The term oligonucleotide also refers to a plurality of nucleotides that are linked together via linkages other than phosphate linkages such as phosphorothioate linkages. The oligonucleotide may be naturally occurring or non-naturally occurring. In a preferred embodiment the oligonucleotides of this invention have between 1-1,000 nucleotides. Oligonucleotides may be synthetic or may be made enzymatically, and, in some embodiments, are 10 to 50 nucleotides in length. Oligonucleotides may include ribonucleotide monomers (i.e., may be oligoribonucleotides) or deoxyribonucleotide monomers. Oligonucleotides may be 10 to 20, 21 to 30, 31 to 40, 41 to 50, 51-60, 61 to 70, 71 to 80, 80 to 100, 100 to 150, 150 to 200, 200 to 500, or greater than 500 nucleotides in length, for example.

[0023] The term “alkyl”, as used herein, refers to a saturated straight chain, branched or cyclic hydrocarbon group of 1 to 24 (i.e., (C₁-C₂₄)alkyl), typically 1-12 (i.e., (C₁-C₁₂)alkyl) carbon atoms, more typically 1-6 carbon atoms (i.e., (C₁-C₆)alkyl), such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The term “lower alkyl” intends an alkyl group of one to six carbon atoms, and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The term “cycloalkyl” refers to cyclic alkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0024] “Alkylene” and “alkylene chain”, as used herein, refer to a straight or branched divalent hydrocarbon chain, linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, preferably having from one to eight carbons, *e.g.*, methylene, ethylene, propylene, *n*-butylene, and the like. The alkylene chain may be attached to the rest of the molecule and to the radical group through one carbon within the chain or through any two carbons within the chain.

[0025] Moreover, the term “alkyl” includes “modified alkyl”, which references an alkyl group having from one to twenty-four (C₁-C₂₀) carbon atoms, and further having additional groups, such as one or more linkages selected from ether-, thio-, amino-, phospho-, oxo-, ester-, and amido-, and/or being substituted with one or more additional groups including lower alkyl, aryl, alkoxy, thioalkyl, hydroxyl, amino, sulfonyl, thio, mercapto, imino, halo, cyano, nitro, nitroso, azide, carboxy, sulfide, sulfone, sulfoxy, phosphoryl, silyl, silyloxy, and boronyl.

[0026] Similarly, the term “lower alkyl” includes “modified lower alkyl”, which references a group having from one to eight carbon atoms and further having additional groups, such as one or more linkages selected from ether-, thio-, amino-, phospho-, keto-, ester-, and amido-, and/or being substituted with one or more groups including lower alkyl; aryl, alkoxy, thioalkyl, hydroxyl, amino, sulfonyl, thio, mercapto, imino, halo, cyano, nitro, nitroso, azide, carboxy, sulfide, sulfone, sulfoxy, phosphoryl, silyl, silyloxy, and boronyl. The term “alkoxy” as used herein refers to a substituent –O–R wherein R is alkyl as defined

above. The term "lower alkoxy" refers to such a group wherein R is lower alkyl. The term "thioalkyl" as used herein refers to a substituent -S-R wherein R is alkyl as defined above.

[0027] The term "aryl", as used herein, refers to aromatic monocyclic or multicyclic, some of which may be fused together, hydrocarbon ring system consisting only of hydrogen and carbon and containing from 6 to 19 carbon atoms (represented as (C₆-C₁₉)aryl), preferably 6 to 10 carbon atoms (represented as (C₆-C₁₀)aryl), where the ring system may be partially or fully saturated. Aryl groups include, but are not limited to groups such as fluorenyl, phenyl and naphthyl. Unless stated otherwise specifically in the specification, the term "aryl" is meant to include aryl radicals optionally substituted by one or more substituents selected from (C₁-C₁₂)hydrocarbyl, -O-R", -O-CO-R", -CO-O-R", -NR'-R", -NR'-CO-R", -CO-NR'-R", -CO-R", -R-O-R", -R-O-CO-R", -R-CO-O-R", -R-NR'-R", -R-NR'-CO-R", -R-CO-NR'-R", -R-CO-R", -CN, halogen, or a combination thereof, wherein R' and R" are independently H or (C₁-C₁₂)hydrocarbyl, and R is (C₁-C₁₂)hydrocarbyl.

[0028] The term "heteroaryl", as used herein, refers to a 5- to 18-membered monocyclic- or bicyclic- or fused polycyclic-ring system which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Preferably heteroaryl is a 5- to 12- or 5- to 9- membered ring system. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzthiazolyl, benzindolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, indoliziny, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl. Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals

as defined above which are optionally substituted by one or more substituents selected from (C₁-C₁₂)hydrocarbyl, -O-R'', -O-CO-R'', -CO-O-R'', -NR'-R'', -NR'-CO-R'', -CO-NR'-R'', -CO-R'', -R-O-R'', -R-O-CO-R'', -R-CO-O-R'', -R-NR'-R'', -R-NR'-CO-R'', -R-CO-NR'-R'', -R-CO-R'', -CN, halogen, or a combination thereof, wherein R' and R'' are independently H or (C₁-C₁₂)hydrocarbyl, and R is (C₁-C₁₂)hydrocarbyl.

[0029] The term "heteroaryl" also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring. Nonlimiting examples include but are not limited to 1-, 2-, 3-, 5-, 6-, 7-, or 8- indoliziny, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8- purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinoliziny, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenoxazinyl, 2-, 3-, 4-, 5-, 6-, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10- benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanly, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10 -, or 11-7H-pyrazino[2,3-c]carbazolyl, 2-, 3-, 5-, 6-, or 7-2H- furo[3,2-b]-pyranly, 2-, 3-, 4-, 5-, 7-, or 8-5H-pyrido[2,3-d]-o-oxazinyl, 1-, 3-, or 5-1H-pyrazolo[4,3-d]-oxazolyl, 2-, 4-, or 5-4H-imidazo[4,5-d] thiazolyl, 3-, 5-, or 8-pyrazino[2,3-d]pyridazinyl, 2-, 3-, 5-, or 6-imidazo[2,1-b] thiazolyl, 1-, 3-, 6-, 7-, 8-, or 9-furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10, or 11-4H-pyrido[2,3-c]carbazolyl, 2-, 3-, 6-, or 7-imidazo[1,2-b][1,2,4]triazinyl, 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 4-, 5-, 6-, or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9- benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-1H-pyrrolo[1,2-b][2]benzazapinyl. Typical fused heteroary groups include, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl.

[0030] The term “cycloalkyl”, as used herein, refers to a stable non-aromatic monocyclic or bicyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, having from three to fifteen carbon atoms, preferably having from three to twelve carbon atoms, (C₃-C₁₂)cycloalkyl, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond, *e.g.*, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalinyl and the like. Unless otherwise stated specifically in the specification, the term "cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents selected from -O-R", -O-CO-R", -CO-O-R", -NR'-R", -NR'-CO-R", -CO-NR'-R", -CO-R", -CN, halogen, or a combination thereof, wherein R' and R" are independently H or (C₁-C₁₂)hydrocarbyl.

[0031] The terms “heterocyclyl” or “heterocycle”, as used herein, refer to an optionally substituted, saturated or partially unsaturated, nonaromatic cyclic group, *e.g.*, which is a 4- to 7-membered monocyclic, 7- to 12-membered bicyclic or 10- to 15-membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heterocyclic group containing a heteroatom may have 1, 2, 3, or 4 heteroatoms selected from nitrogen atoms, oxygen atoms and sulfur atoms, wherein the nitrogen and sulfur heteroatoms may also optionally be oxidized. The heterocyclic group may be attached at a heteroatom or a carbon atom. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. The bicyclic and tricyclic heterocyclyl groups can be fused or spiro rings or ring groups. Preferably heterocyclyl is a 4- to 12-membered ring system. Also preferably heterocyclyl is a 4- to 9-membered ring system.

[0032] Exemplary monocyclic heterocyclic groups include oxetanyl, thiatanyl, azetidiny, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolidiny, dihydropyrazolyl, tetrahydropyrazolyl, dihydropyridiny, tetrahydropyridiny, dihydrothiopyranyl, tetrahydrothiopyranyl, pyranyl, dihydropyranyl, tetrahydropyranyl, thiopyranyl, dihydrothiopyranyl, tetrahydrothiopyranyl, piperidiny, piperazinyl, morpholinyl, azepiny, dihydroazepiny, tetrahydroazepiny, 2-oxopiperazinyl, 2-oxopiperidiny, 2-oxopyrrolidiny, 2-oxoazepiny, oxepanyl, thiepanyl, dihydrothiepanyl, tetrahydrothiepanyl, dihydrooxepiny, tetrahydrooxepiny, 1,4-dioxanyl, 1,4-oxathianyl,

morphoiiinyl, oxazolyl, oxazolidinyl, isoxazolinyi, A- pteridony!, isoxazoiinyi, isoxazolyl, 1,4-azathianyl, 1,4-oxathiepanyl, 1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thieaxepanyl, 1,4-diazepanyl, tropanyl, 3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, thiazolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorphoiiinyl suifone, 1,3-dioxolane and tetrahydro-1,1-dioxothienyl, 1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl, pyrazolinyl, and the like.

[0033] Exemplary bicyclic heterocyclic groups include but are not limited to, dihydroindolyl, quinuctidinyl, tetrahydroquinolinyl, decahydroquinolinyl, 2-oxa-6-azaspiro[3,3]heptan-6-yl, tetrahydroisoquinoiinyi, decahydroisoquinoiinyi, dihydroisoindolyl, indoiinyi, norboranyl, adamantanyl, and the like.

[0034] Unless stated otherwise specifically in the specification, the term “heterocyclyl” is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from $-O-R'$, $-O-CO-R'$, $-CO-O-R'$, $-NR'-R'$, $-NR'-CO-R'$, $-CO-NR'-R'$, $-CO-R'$, $-CN$, halogen, or a combination thereof, wherein R' and R'' are independently H or (C_1-C_{12}) hydrocarbyl.

[0035] The term “direct bond”, as used herein, means that the two entities linked by the “direct bond” are connected to each other directly. The direct bond may be a single bond or a double bond, for example.

[0036] The term “DNA”, or “deoxyribonucleic acid”, as used herein, refers to a polynucleotide or oligonucleotide that comprises at least one deoxyribonucleotide residue.

[0037] The term “RNA”, or “ribonucleic acid”, as used herein, refers to a polynucleotide or oligonucleotide that comprises at least one ribonucleotide residue.

[0038] As used herein, a “linker” bridges two moieties in a molecule. A “linker” may be a hydrocarbyl chain (e.g., (C_1-C_{12}) alkylene, (C_2-C_{12}) alkenylene), optionally substituted with a substituent group, or a linker may be a hydrocarbyl chain interspersed with other atoms, as represented by $-(CHR')_a-W_b-(CHR')_c-V_d-(CHR')_e-$, wherein W and V are independently $-O-$, $-S-$, or $-NR'$; R' is H or (C_1-C_6) alkyl; and a , b , c , d , and e are independently an integer from 0 to 10, preferably from 0 to 6, or preferably from 0 to 3, and the sum of a , b , c , d , and e is preferably an integer from 2 to 6. The optional substituent group may be $-O-R'$, $-O-CO-R'$, $-NR'-R'$, $-NR'-CO-R'$, $-CO-NR'-R'$, $-CO-R'$, $-CN$, halogen, or a combination thereof, wherein R' and R'' are independently H or (C_1-C_6) hydrocarbyl.

[0039] The term “polyethylene glycol”, as used herein, refers to polyether compounds having a formula $R-(O-CH_2-CH_2)_n-O-R'$, wherein R and R' are independently H or an alkyl. “Polyethylene glycol derivative” refers to polyether compounds having a formula $R-(O-CH_2-CH_2)_n-X-R'$, wherein R and R' are independently H or an alkyl, and X is O or NH.

[0040] The term “polypeptide”, as used herein, refers a molecule containing a plurality of amino acids linked by peptide bonds. A polypeptide may be generated from a natural protein or chemically synthesized.

[0041] The term “protein”, as used herein, refers to a molecule containing one or more polypeptides. A protein is often of natural origin, but may include those modified from a natural protein.

[0042] The terms “polysaccharide” or “polycarbohydrate”, as used herein, refer to a carbohydrate molecule having a plurality of sugar moieties linked by glycosidic bonds.

[0043] “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not. For example, the phrase “optionally substituted” means that a non-hydrogen substituent may or may not be present, and, thus, the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present.

Detailed Description of the Invention

[0044] Embodiments of the invention relate to methods for conjugating oligonucleotides with other molecules or target entities. The oligonucleotides may include DNA, RNA, or a chimeric DNA/RNA. The target entities may be any desired targets, such as other oligonucleotides, proteins/peptides, carbohydrates, or supports (which may include soluble polymers or solid supports, such as resins, glass beads, magnetic beads, matrix surfaces, etc.).

[0045] Embodiments of the invention are based on the fact that squaric acid and derivatives thereof can be readily coupled with amino groups under mild conditions. These conjugation processes provide simple aqueous based methods for producing oligonucleotide conjugates. The products from these reactions are stable and can be readily isolated and stored. In addition, squaric acid derivatives have been used in modifications of pharmaceuticals and are found to be nontoxic.

[0046] **FIG. 1** shows the structure of squaric acid (i.e., cyclobutene 3,4 dione), which can be reacted with alcohols to give squaric diesters. The esterification can easily occur in the presence of an acid catalyst, as in the usual esterification of carboxylic acids. Nucleophilic substitution of the squaric acid esters can readily occur, e.g., with amines as nucleophiles to give the corresponding monoamides or diamides. These properties can be used in many applications, including modification of biological molecules to change their properties.

[0047] In addition to the esters, other squaric acid derivatives that can also be used to react with nucleophiles (e.g., amino groups or thiol groups) include squaric halides, squaric ester halide, and squaric imidazoles. All these squaric acid derivatives may be used with embodiments of the invention, and all these reagents can react with oligonucleotides having amino or thiol functional groups. Embodiments of the invention preferably use squaric acid diesters as the reagents.

[0048] The use of squaric acid derivatives has been described for conjugations with small molecules, and for conjugation of small molecules to proteins or carbohydrates. It has also been used to couple large molecules, such as a 20K polysaccharide to a protein. In addition, U.S. Patent No. 6,602,692, issued to Glösenkamp et al., discloses the use of squaric acid derivatives to conjugate peptides to solid support that has been modified with a squaric derivative. The disclosure of the '692 patent is incorporated by reference in its entirety.

[0049] Embodiments of the invention may use any of the above squaric acid derivatives. Preferred embodiments of the invention use squaric acid esters, which may be referred generally as squarate. The squaric acid esters are diesters, wherein the two ester groups (-OR groups) maybe the same or different.

[0050] While the uses of squarate to conjugate various molecules are known, no applications using this technology for conjugations to DNA or RNA have been reported. Considerable efforts have been directed to the application of oligonucleotides and oligonucleotide analogs as diagnostic/research reagents or as potential therapeutics. Examples of potential applications of oligonucleotides as pharmaceuticals may include antisense oligonucleotides that can bind to certain coding regions to prevent the expression of proteins or to block various cell functions. Furthermore, the development of SELEX techniques (Systematic Evolution of Ligands by Exponential Enrichment) (Tuerk and Gold, Science, 249:505 (1990)) makes it possible to identify oligonucleotides that will bind to almost any biologically interesting targets.


[0051] The potential uses of oligonucleotides as pharmaceutical agents have led to further development of various chemical modifications aiming to increase their therapeutic activities and stabilities. Such modifications may increase cell penetration of the oligonucleotides or their resistance to nucleases. In addition, these modifications may enhance the bindings of oligonucleotides to their targets or may improve the pharmacokinetic properties of the oligonucleotides. Therefore, methods that can easily modify oligonucleotides for various applications are desirable.

[0052] Embodiments of the invention provide methods for the modifications of oligonucleotides under very mild conditions and they methods are suitable for applications in the modifications of oligonucleotide pharmaceuticals. In accordance with embodiments of the invention, oligonucleotide derivatives (containing reactive functional groups for coupling with squaric acid derivatives) may be prepared with any suitable methods. For example, the oligonucleotides may be synthesized with a reactive functional group (e.g., an amino group) for coupling with a squaric acid derivative. The reactive functional groups, for example, may be an amino group or a thiol group.

[0053] Various methods for attaching functional groups to oligonucleotides are known. (For a review, see Goodchild, *Bioconjugate Chemistry*, 1:165-187 (1990)). Once the chemically reactive functional groups are attached to oligonucleotides (e.g., at the 5'- and or 3'terminus), these reactive functional groups can be used to couple with various conjugates. For example, a primary aliphatic amino group may be incorporated at the 5'-terminus of the oligonucleotide in the final step of the synthesis of an oligonucleotide. Reagents for linking to the 5' terminus of an oligonucleotide are commercially available. For example, various linkers having different lengths of $-(CH_2)_n-$ connectors for linking to the 5' terminus of an oligonucleotide are available. One example is 5'-Amino-Modifier C6 is available from Glen Research Corp. (Sterling, Va.). Amino modifiers for the 3' end of oligonucleotides are also readily available, either as phosphoramidites or already attached to the synthesis solid support.


[0054] The reagents used to modify the oligonucleotides to provide reactive functional groups may be in the form of phosphoramidites, which may be coupled to the free 5'-hydroxyl group of the full length oligonucleotide while it is attached to a solid support. This coupling would be like attaching another nucleotide monomer. (See, e.g., Theison et al., *Tetrahedron Lett.*, 33:5033-5036 (1992).)

[0055] In accordance with some embodiments of the invention, the reactive groups (e.g., amino or thiol groups) may be attached to the oligonucleotides using modified nucleotides. In this case, the reactive groups need not be attached to the 5' or 3' end. Instead, one can use these modified nucleotide analogs to incorporate the reactive groups at the internal positions. Some examples of such modified nucleotides are shown below:



[0056] In the above examples, R_1 is H or OH. Formula (I) represents a natural nucleoside or deoxynucleoside (R is H or OH), and formulae (II) – (IV) (wherein n is an integer greater than 0) represent various analogs having reactive amino groups modifications on the sugar rings. These amino groups will be protected during incorporation of these analogs into oligonucleotides. Some of these reagents are commercially available or may be prepared according to procedures known in the art.

[0057] Other modified nucleotide analogs may have modifications on the purine or pyrimidine rings, such as those shown below:



[0058] The above formulae (V) –(X) (wherein n is an integer greater than 0) show examples of nucleotide analogs that contain reactive amino groups. These analogs may be used to incorporate into oligonucleotides after these amino groups have been protected. Some of these reagents are commercially available or may be prepared according to procedures known in the art.

[0059] Once the oligonucleotides are derivatized with reactive functional groups (e.g., amino or thiol groups), they may be used to couple with squaric acid derivatives. The following examples illustrate some embodiments of the invention.

[0060] In accordance with some embodiments of the invention, the oligonucleotide-squarate mono conjugates could be used to attach oligonucleotides to other target entities, such as peptides, proteins, oligosaccharides, solid surfaces, polymeric materials, nanoparticles, hydrogels, and small molecules.

[0061] In accordance with some embodiments of the invention, these mono conjugates can be used to couple with other handles that may be selected for particular purposes. One example of such application is to attach a diene moiety (e.g., a furan) to a oligonucleotide-squarate mono adduct in order for this to participate in a Diels Alder reaction with a dienophile-linked molecule (e.g., N-ethyl maleimide), which is disclosed in a co-pending application filed on the same day.

[0062] It should be noted that while examples described herein use amino groups to conjugate with a squarate, other nucleophilic groups (e.g., thiol) may also be used.

[0063] Treatment of the oligonucleotide mono squarate with limited amounts of species containing more than one amine (eq. di amines, tri amines, to polyamines) would provide a means to make mutimeric oligonucleotide structures.

[0064] Another application of this conjugation may be the coupling of two amino labeled oligonucleotides together to form cyclical or hairpin-type oligonucleotide structures. The oligonucleotides could be complimentary sequences, with a 3' amino label on one strand and a 5' amino label on the other. This would form a hairpin like dimer.

[0065] Advantages of the invention may include one or more of the following. Embodiments of the invention provide easy and efficient methods for the conjugation of oligonucleotides to various target entities. The reactions with squarates can be conducted in aqueous solutions with high yields and the products can be easily purified (e.g., by ultra filtration or by size exclusion chromatography). The mono-squarate adducts are stable and can be purified and stored for later uses.

[0066] The stability of the mono conjugate with DNA/RNA might allow coupling of a second amino labeled oligonucleotide that is not complementary to the sequence of the oligonucleotide-mono squarate species. The coupling of two non-complimentary oligonucleotides is very difficult to do non-enzymatically. Methods of the invention would provide access to these molecules. The squaric acid derivatives are small and would not illicit immunogenic responses, resulting in fewer adverse reactions when incorporating the functionality into pharmaceuticals.

Examples

Synthesis of oligonucleotide-squarate mono conjugate

[0067] An oligonucleotide is synthesized with an amino linker attached, using any method know in the art (see the above discussion). The example shown in **FIG. 2** uses a TFA-protected amine C6 linker phosphoramidite (i.e., $\text{CF}_3\text{-CO-NH-(CH}_2\text{)}_6\text{-O-P((O-CH(CH}_3\text{)}_2)_2\text{(O-CH}_2\text{-CH}_2\text{-CN))}$), which is coupled to the 5'-OH end of the oligonucleotide on solid support using the appropriate synthesis conditions. This coupling may be carried out under conditions similar to the coupling of a nucleotide monomer and can be performed while the oligonucleotide is still attached to a solid support. After the synthesis and deprotection as usual (standard ammonia and TEA 3HF for RNA), the mixture may be

ultrafiltered against NaCl to remove all ammonia and ammonium salts. Finally, the retentate is washed with water to remove all excess salts. The oligonucleotide solution may then be concentrated down. The concentrate may be lyophilized or used as is.

[0068] Once the amino-labeled oligonucleotide is available, it can be coupled to a squaric acid derivative. For example, a solution of amino-labeled oligonucleotide, approximately 10 mg in 500 μ L of 300 mM sodium phosphate, pH 7-8 was prepared. To this was added an excess of dimethyl ester of squaric acid (dimethoxy cyclobutene 1,2 dione; approx. 0.75 mg to each mg of oligonucleotide), as shown in **FIG. 2**. Excess squaric ester is used to favor the formation of mono-substituted squarate derivative and to suppress the formation of di-substituted squarate derivatives.

[0069] The reaction mixture was kept at 25° C and the pH of the solution was adjusted with dibasic phosphate to maintain the reaction pH between 7 and 7.8, as the pH tends to drop during conjugation. After about 4 hours, the reaction solution was filtered and washed with water in a 3K ultrafiltration (UF) spin cartridge to remove remaining small molecules. (e.g., excess squaric ester and salts). The UF retentate was lyophilized and analyzed by LCMS, which confirmed the formation of the desired product – i.e., an oligonucleotide-squarate mono adduct. Such adducts are very stable. For example, these mono substituted squarates are found to be stable for at least two days in aqueous solutions at pH = 7, and for over 1 year at 4°C as a lyophilized solid.

[0070] Alternatively, the reaction solution may be filtered and washed with water, followed by washing with a borate buffer, which may be used as the buffer for the next reaction and used directly in the next conjugation step (e.g., conjugation to a target entity shown below).

[0071] The above described coupling reaction is very efficient. The reactions have been run many times and these reactions are found to proceed to 90 – 99% completion, as judged by the amount of starting amino labeled oligonucleotides remaining after the conjugation. The reactions can be easily monitored by LCMS analysis.

Reaction of oligonucleotide-squarate mono conjugate with a target entity

[0072] The lyophilized squarate mono conjugate was taken up in a 25 mM sodium borate buffer, pH = 9.2, and treated with an excess (e.g., 10-40 folds) of a target entity containing an

amino group (e.g., NH₂-R) dissolved in a small amount of DMSO, as shown in **FIG. 3**. The mono conjugate pre-ultrafiltered in 25 mM borate buffer (see above) could be treated directly with the amine/DMSO mixture, without lyophilization and re-dissolution.

[0073] In this particular example, the target entity is a 5-methyl furfuryl amine (i.e., R = 5-methyl-furfuryl). The reaction was run at room temperature for 2 hours. The reaction mixture was again concentrated and washed in the 3K UF spin cartridges to remove excess amine and salts. The retentate was lyophilized and a portion of the solid analyzed by LCMS, which showed the desired conjugate was formed in approximately 95% yield, based on starting mono conjugate.

[0074] Based on these protocols, various target entities have been conjugated with oligonucleotides. Some examples of these conjugations are shown in **FIG. 4**. The preparations of PEG-oligonucleotide conjugates are known, see e.g., Goodchild et al., *Bioconjugate Chem.*, 1:165 (1990); and Zalipsky et al., *Bioconjugate Chem.*, 6:150 (1995). The PEG conjugates can be used to improve the in vivo stabilities of the oligonucleotides and/or to reduce the immunogenicities of the oligonucleotides.

Formation of oligonucleotide duplex with two complimentary oligonucleotides

[0075] An RNA 20 mer that contained a 5' Hexaethylene glycol (HEG) spacer linker followed by the standard six carbon amino linker was made using standard oligonucleotide solid phase synthesis techniques. The HEG and C6 amino linkers (both are commercially available) were added as phosphoramidites using standard oligonucleotide synthesis / deprotection protocols, see example 1 above. The crude RNA was purified by anion exchange chromatography and ultrafiltered on a 2K Hydrosart membrane prior to lyophilization. LCMS analysis of the lyophilized material gave the expected molecular weight of the modified oligonucleotide. 150 mg of this lyophilized amino modified RNA was taken up in 3.0 mL of sodium phosphate giving a solution with a pH range of 7-8. To this solution was added 100 mg of dimethoxy squarate dissolved in 300 uL of DMSO. LCMS analysis after 1 hour showed that the amino labeled RNA had been converted completely over to the desired mono squarate, as shown in **FIG 5**.

[0076] The complimentary sequence to the one mentioned in the above section (0074) was made using the same standard synthesis protocols used, in this case with a 3' amino linker attached, see **FIG 5**. The modified RNA was deprotected, purified, ultrafiltered and

lyophilized using the same procedures as used in the preparation of the 5' amino labeled RNA. 10 mg of the lyophilized 5' amino RNA was dissolved in 400 uL of water. 11 mg (approx. 1.2 fold excess) of the lyophilized 3' amino RNA complement was dissolved in a separate 400 uL of water. The two solutions were combined and warmed to 50-60°C for approximately 5 minutes, the solution was allowed to cool to room temperature over 30 minutes. To this solution was then added 300 uL of 150 mM sodium borate which brought the solution pH to approximately 9 (by pH paper). This mixture was allowed to stand at room temperature for 3 hours. LCMS analysis of a sample of this reaction showed that the dimer had been cleanly formed, with no hydrolyzed mono RNA squarate observed.

Conjugates of two oligonucleotides


[0077] In addition, the stability of mono conjugates of squarate with oligonucleotides (e.g., DNA or RNA) permits one to isolate the mono-conjugate intermediates and use them to couple with a second oligonucleotide, even if the second amino-labeled oligonucleotide is not complementary to the sequence of the oligonucleotide-squarate mono adduct. The coupling of two non-complimentary oligonucleotides (particularly when one oligonucleotide is DNA and the other is RNA) is very difficult to do non-enzymatically. Methods of the invention would provide access to these molecules.

Formation of cyclic oligonucleotides

[0078] As noted above, the stability of mono conjugates of squarate with oligonucleotides (e.g., DNA or RNA) permits one to isolate the mono-conjugate intermediates and use them to couple with a second oligonucleotide later. One may take advantage of this property and use these mono-conjugates to conjugate with second amino groups (which may be temporarily protected during the first stage of the conjugation) present at the other terminus of the oligonucleotides to form cyclic oligonucleotides.


Conjugation with secondary amines

Oligonucleotide mono squarate conjugation with peptides




[0079] To 100 μ L of a 100 mM sodium borate buffered solution (pH = 9.2) of the mono methoxy squarate labeled RNA 20 mer, approximately 1 μ M, was added and excess of the tripeptide, Leu-Gly-Gly, dissolved 100 μ L of 100 mM sodium borate buffered solution (pH = 9.2). This mixture left at 25°C for 1.5 hours. LCMS analysis of the reaction mixtures showed that the peptide conjugate was produced in approximately 85% yield, also see **FIG 6**.

Oligonucleotide mono squarate conjugation with lipids



[0080] To 75 μ L of 100 mM sodium borate buffered solution (pH = 9.2) of the mono methoxy squarate labeled RNA 20 mer, at approximately 1 μ M, was added a small excess of shingosine dissolved 75 μ L of isopropanol. This mixture left at 25°C for 30 minutes. LCMS analysis of the reaction mixtures showed that the lipid conjugate was produced in approximately 60% yield, also see **FIG 6**.

Oligonucleotide mono squarate conjugation with isopropyl amine



[0081] To 150 μ L of a 100 mM sodium borate buffered solution (pH = 9.2) of the mono methoxy squarate labeled RNA 20 mer, approximately 1 μ M, was added and excess of isopropyl amine dissolved 20 μ L of DMSO. After 4 hours at 25°C LCMS analysis of the

reaction mixtures showed that the isopropyl amine derivative was formed in over 95% yield, also shown in **FIG 6**.

[0082] It is noted that the amino/thio labeled oligonucleotide can be added to an already derivatized mono squarate, inverting the order of addition. The mono squarate of a small molecule amine/thio, or peptide, protein, etc. can be made first and then treated with an amino/thio labeled oligonucleotide to form the squarate oligonucleotide conjugate.

[0083] In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference, unless the context clearly dictates otherwise.

[0084] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described. Methods recited herein may be carried out in any order that is logically possible, in addition to a particular order disclosed.

[0085] While the invention has been described with respect to a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that other embodiments can be devised which do not depart from the scope of the invention as disclosed herein. Accordingly, the scope of the invention should be limited only by the attached claims.

Incorporation by Reference

[0086] References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made in this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material explicitly set forth herein is only incorporated to the extent that no conflict arises between that incorporated material and the present disclosure material. In the event of a conflict, the conflict is to be resolved in favor of the present disclosure as the preferred disclosure.


Equivalents

[0087] The representative examples disclosed herein are intended to help illustrate the invention, and are not intended to, nor should they be construed to, limit the scope of the invention. Indeed, various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including the examples which follow and the references to the scientific and patent literature cited herein. The following examples contain important additional information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.

What is claimed is:


CLAIMS

1. An oligonucleotide derivative having the structure of formula (A):



- wherein R^3 is a first oligonucleotide; R^1 is selected from the group consisting of alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide; R^2 is a linker or a direct bond; Z^1 is NR^4 , S, or O, and Z^2 is NR^4 or S, wherein R^4 is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl.
2. The oligonucleotide derivative of claim 1, wherein R^2 is a (C_1 - C_{12}) linker attached to a 5' hydroxy group, a 3' hydroxy group, or an exocyclic amino group on a nucleobase of the first oligonucleotide.
3. The oligonucleotide derivative of any of claims 1-2, wherein Z^2 is NH.
4. The oligonucleotide derivative of any of claims 1-3, wherein R^1 is a (C_1 - C_{12}) alkyl and Z^1 is O.
5. The oligonucleotide derivative of any of claims 1-3, wherein R^1 is a 1K – 80K polyethylene glycol and Z^1 is NH.
6. The oligonucleotide derivative of any of claims 1-3, wherein R^1 is a second oligonucleotide and Z^1 is NH.
7. The oligonucleotide derivative of claim 6, wherein the second oligonucleotide is complementary to the first oligonucleotide.
8. A method for preparing an oligonucleotide-squarate derivative, comprising:

- a. synthesizing an oligonucleotide derivative comprising an amino or thiol group; and
 - b. reacting a 3,4-dialkoxycyclobutene-1,2-dione with the oligonucleotide derivative to produce an oligonucleotide-squarate mono-conjugate.
9. The method of claim 8, wherein the oligonucleotide derivative comprises a linker that comprises the amino or thiol group.
 10. The method of claim 8, further comprising reacting the oligonucleotide-squarate mono-conjugate with a target entity selected from a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second oligonucleotide.
 11. The method in claim 8, further comprising reacting the oligonucleotide-mono-squarate with a amine/thio labeled surface selected from array surfaces, hydrogels, nanoparticles, soluble and insoluble polymers.
 12. The method of claim 8, wherein the oligonucleotide derivative comprises a second amino or thiol group at a second location in the oligonucleotide derivative, the method further comprising forming an intra-oligonucleotide crosslink creating a cyclic structure.
 13. The method of claim 8, wherein the oligonucleotide mono squarate is combined with a multi-amine/thio containing species to provide a material with multiple attachments of the oligonucleotide via the squarate.
 14. A compound having the structure of formula (A):



wherein R^3 is a first oligonucleotide; R^1 is selected from the group consisting of a polyethylene glycol, a peptide, a protein, a polysaccharide, and a second

oligonucleotide; R^2 is a linker or a direct bond; Z^1 is NR^4 , S, or O, and Z^2 is NR^4 or S, wherein R^4 is selected from H, alkyl, aryl, heterocyclyl, or heteroaryl.

15. The compound of claim 14, wherein R^1 is a polyethylene glycol.
16. The compound of claim 14, wherein R^1 is a peptide.
17. The compound of claim 14, wherein R^1 is a second oligonucleotide.
18. The compound of claim 17, wherein the second oligonucleotide is complementary to the first oligonucleotide.
19. The compound of claim 14, wherein each of Z^1 and Z^2 is NH.
20. The compound of claim 14, wherein Z^1 is O and Z^2 is NH.
21. The compound of claim 15, wherein R^1 is a 20k – 40k polyethylene glycol and Z^1 is NH.
22. The compound of claim 17, wherein the second oligonucleotide comprises about 2 to about 200 nucleotides and Z^1 is NH.




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

A. CLASSIFICATION OF SUBJECT MATTER**C07H 19/00(2006.01)i, C07H 19/052(2006.01)i, C07H 19/167(2006.01)i, C07H 21/00(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07H 19/00; C07H 21/04; A61B 5/055; C07D 239/54; C07F 5/00; C07H 19/052; C07H 19/167; C07H 21/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: oligonucleotide, squarate, squaric acid, conjugation

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YAN, H. et al. Bioorganic & Medicinal Chemistry Letters. 2007, Vol 17, pages 6535-6538 See abstract; page 6535-6536; Schemes 3,4.	1,3,8-10,14,19
A		2,11-13,15-18,20-22
A	JP 2005-247706 A (JAPAN SCIENCE & TECHNOLOGY AGENCY) 15 September 2005 See abstract; paragraph [0002]; claim 1.	1-3,8-22
A	US 6140494 A (HAMILTON, A. L. et al.) 31 October 2000 See column 1, lines 63-67; claim 1; Table 1.	1-3,8-22
A	WO 2009-156421 A1 (TOPOTARGET) 30 December 2009 See pages 11-21; claim 1.	1-3,8-22
A	US 2011-0092806 A1 (PORT, M. et al.) 21 April 2011 See paragraphs [0078],[0116]; claims 1,2.	1-3,8-22



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family


Date of the actual completion of the international search

26 July 2013 (26.07.2013)

Date of mailing of the international search report

26 July 2013 (26.07.2013)

Name and mailing address of the ISA/KR


 Korean Intellectual Property Office
 189 Cheongsa-ro, Seo-gu, Daejeon Metropolitan City,
 302-701, Republic of Korea

Facsimile No. +82-42-472-7140

Authorized officer

HONG Sung Ran

Telephone No. +82-42-481-5405



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2013/038703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2005-247706 A	15/09/2005	None	
US 6140494 A	31/10/2000	EP 0898596 A1 EP 0898596 B1 JP 2000-508709 A WO 97-40104 A1	18/07/2001 29/08/2001 11/07/2000 30/10/1997
WO 2009-156421 A1	30/12/2009	AU 2009-264273 A1 CA 2728806 A1 CN 102123988 A EP 2318369 A1 JP 2011-525522 A MX 2010014310 A RU 2011102444 A US 2012-0225847 A1	30/12/2009 30/12/2009 13/07/2011 11/05/2011 22/09/2011 15/02/2011 27/07/2012 06/09/2012
US 2011-0092806 A1	21/04/2011	CA 2625196 A1 CA 2625207 A1 CN 101305006 A CN 101305006 B CN 101305006 C EP 1931673 A1 EP 1931673 B1 EP 1940841 A2 EP 2457914 A1 JP 2009-513574 A JP 2009-519209 A KR 10-2008-0080495 A US 2009-0169479 A1 US 2012-0064003 A1 US 8114863 B2 WO 2007-042504 A2 WO 2007-042504 A3 WO 2007-042506 A1	19/04/2007 19/04/2007 12/11/2008 24/04/2013 12/11/2008 18/06/2008 29/08/2012 09/07/2008 30/05/2012 02/04/2009 14/05/2009 04/09/2008 02/07/2009 15/03/2012 14/02/2012 19/04/2007 28/02/2008 19/04/2007